Sandoz Antitrust Claims Nixed In Bayer’s Yasmin IP Suit

Law360, New York (September 28, 2011, 6:43 PM EDT) -- A New York federal judge on Wednesday dismissed antitrust counterclaims brought by drugmaker Sandoz Inc. in Bayer Schering Pharma AG’s patent infringement suit over a generic version of oral contraceptive Yasmin, effectively ending the dispute.

Bayer originally brought the suit in April 2008, seeking to block Sandoz and Watson Pharmaceuticals Inc. from marketing a generic version of the oral contraceptive.

Despite winning a judgment of noninfringement in September 2010, Sandoz had pressed ahead with its counterclaims alleging Sherman Act violations by Bayer and accusing the Leverkusen,...
To view the full article, register now.